SRR8943005
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.500
- MYC_TARGETS_V2+0.440
- G2M_CHECKPOINT+0.350
- E2F_TARGETS+0.340
- OXIDATIVE_PHOSPHORYLATION+0.280
- MITOTIC_SPINDLE+0.220
- UNFOLDED_PROTEIN_RESPONSE+0.190
- DNA_REPAIR+0.170
- TGF_BETA_SIGNALING+0.140
- ADIPOGENESIS+0.040
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.590
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.560
- IL6_JAK_STAT3_SIGNALING-0.540
- INFLAMMATORY_RESPONSE-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- TNFA_SIGNALING_VIA_NFKB-0.480
- ANGIOGENESIS-0.430
- KRAS_SIGNALING_UP-0.420
- COMPLEMENT-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR26320084 | — | — | 0.920 |
| 2 | C3L-04013 | — | cohortMD1 | 0.915 |
| 3 | 74f8dc07-b42e-46a4-954f-a36d7bf664d3 | — | — | 0.914 |
| 4 | 15d39440-6bb8-4ecb-add1-9ae8b007dc70 | — | — | 0.913 |
| 5 | TCGA-2F-A9KP-01A-11R-A38B-07 | — | — | 0.909 |
| 6 | c698e8a5-cea5-4d25-953b-674cf45b64d5 | — | — | 0.907 |
| 7 | sclcMAD04148_S54.txt | — | cohortSC | 0.906 |
| 8 | SRR5088887 | — | — | 0.905 |
| 9 | TCGA-22-A5C4-01A-12R-A27Q-07 | — | cohortSQ1 | 0.904 |
| 10 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |